234 related articles for article (PubMed ID: 14565648)
41. Myelodysplastic transformation in a case of essential thrombocythemia treated with pipobroman.
Messora C; Bensi L; Vanzanelli P; Temperani P; Carotenuto M; Sacchi S
Haematologica; 1996; 81(1):51-3. PubMed ID: 8900853
[TBL] [Abstract][Full Text] [Related]
42. The leukemia controversy in myeloproliferative disorders: is it a natural progression of disease, a secondary sequela of therapy, or a combination of both?
Barbui T
Semin Hematol; 2004 Apr; 41(2 Suppl 3):15-7. PubMed ID: 15190518
[TBL] [Abstract][Full Text] [Related]
43. Clinical features of polycythemia vera and essential thrombocythemia in Japan: retrospective analysis of a nationwide survey by the Japanese Elderly Leukemia and Lymphoma Study Group.
Dan K; Yamada T; Kimura Y; Usui N; Okamoto S; Sugihara T; Takai K; Masuda M; Mori M;
Int J Hematol; 2006 Jun; 83(5):443-9. PubMed ID: 16787877
[TBL] [Abstract][Full Text] [Related]
44. [Treatment of polycythemia vera with hydroxyurea or pipobroman. Efficacy and toxicity analysed from a protocol of 96 patients under 65 years of age. Le Groupe d'Etude des Polyglobulies].
Najean Y
Presse Med; 1992 Nov; 21(37):1753-7. PubMed ID: 1488420
[TBL] [Abstract][Full Text] [Related]
45. Busulfan versus hydroxyurea in the treatment of polycythemia vera (PV) and essential thrombocythemia (ET).
Brodsky I
Am J Clin Oncol; 1998 Feb; 21(1):105-6. PubMed ID: 9499248
[No Abstract] [Full Text] [Related]
46. Risk-adapted therapy in essential thrombocythemia and polycythemia vera.
Finazzi G; Barbui T
Blood Rev; 2005 Sep; 19(5):243-52. PubMed ID: 15963833
[TBL] [Abstract][Full Text] [Related]
47. [Management of polycythaemia with pipobroman].
Perreau-Boutet MC; Najman A; Stachowiak J; Parlier Y; Gorin NC; Duhamel G
Nouv Presse Med; 1982 Sep; 11(34):2549-53. PubMed ID: 7133977
[TBL] [Abstract][Full Text] [Related]
48. Current management strategies for polycythemia vera and essential thrombocythemia.
Guglielmelli P; Vannucchi AM
Blood Rev; 2020 Jul; 42():100714. PubMed ID: 32546373
[TBL] [Abstract][Full Text] [Related]
49. Acute coronary disease in essential thrombocythemia and polycythemia vera.
Rossi C; Randi ML; Zerbinati P; Rinaldi V; Girolami A
J Intern Med; 1998 Jul; 244(1):49-53. PubMed ID: 9698024
[TBL] [Abstract][Full Text] [Related]
50. Historical perspective on the treatment of essential thrombocythemia and polycythemia vera.
Gilbert HS
Semin Hematol; 1999 Jan; 36(1 Suppl 2):19-22. PubMed ID: 9930553
[TBL] [Abstract][Full Text] [Related]
51. Transition of essential thrombocythemia to megakaryoblastic leukemia after long-term therapy with sequential busulfan, pipobroman and hydroxyurea.
Sironi M; Bertola G; Lodato A; Spinelli M; Sciariada L
Acta Haematol; 2003; 109(3):161-2. PubMed ID: 12714827
[No Abstract] [Full Text] [Related]
52. Allogeneic Hematopoietic Stem Cell Transplantation for Post-essential Thrombocythemia and Post-polycythemia Vera Myelofibrosis.
Murata M; Suzuki R; Nishida T; Shirane S; Shimazu Y; Minami Y; Mori T; Doki N; Kanda Y; Uchida N; Tanaka M; Ishikawa J; Togitani K; Fukuda T; Ichinohe T; Atsuta Y; Nagamura-Inoue T; Kiyoi H
Intern Med; 2020; 59(16):1947-1956. PubMed ID: 32801269
[TBL] [Abstract][Full Text] [Related]
53. Therapeutic options for patients with polycythemia vera and essential thrombocythemia refractory/resistant to hydroxyurea.
Sever M; Newberry KJ; Verstovsek S
Leuk Lymphoma; 2014 Dec; 55(12):2685-90. PubMed ID: 24524340
[TBL] [Abstract][Full Text] [Related]
54. Non-adherence to treatment with cytoreductive and/or antithrombotic drugs is frequent and associated with an increased risk of complications in patients with polycythemia vera or essential thrombocythemia (OUEST study).
Le Calloch R; Lacut K; Le Gall-Ianotto C; Nowak E; Abiven M; Tempescul A; Dalbies F; Eveillard JR; Ugo V; Giraudier S; Guillerm G; Lippert E; Berthou C; Ianotto JC
Haematologica; 2018 Apr; 103(4):607-613. PubMed ID: 29246923
[TBL] [Abstract][Full Text] [Related]
55. Long term follow up of 93 families with myeloproliferative neoplasms: life expectancy and implications of JAK2V617F in the occurrence of complications.
Malak S; Labopin M; Saint-Martin C; Bellanne-Chantelot C; Najman A;
Blood Cells Mol Dis; 2012 Oct 15-Dec 15; 49(3-4):170-6. PubMed ID: 22818858
[TBL] [Abstract][Full Text] [Related]
56. Primary thrombocythemia.
Jamshidi K; Ansari A; Windschitl HE; Swaim WR
Geriatrics; 1973 Jan; 28(1):121-33. PubMed ID: 4539498
[No Abstract] [Full Text] [Related]
57. Proposal for revised diagnostic criteria of essential thrombocythemia and polycythemia vera by the Thrombocythemia Vera Study Group.
Michiels JJ; Juvonen E
Semin Thromb Hemost; 1997; 23(4):339-47. PubMed ID: 9263350
[TBL] [Abstract][Full Text] [Related]
58. Prediction of thrombosis in post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a study on 1258 patients.
Mora B; Guglielmelli P; Kuykendall A; Rumi E; Maffioli M; Palandri F; De Stefano V; Caramella M; Salmoiraghi S; Kiladjian JJ; Gotlib J; Iurlo A; Cervantes F; Ruggeri M; Silver RT; Albano F; Benevolo G; Ross DM; Della Porta MG; Devos T; Rotunno G; Komrokji RS; Casetti IC; Merli M; Brociner M; Caramazza D; Auteri G; Barbui T; Cattaneo D; Bertù L; Arcaini L; Vannucchi AM; Passamonti F
Leukemia; 2022 Oct; 36(10):2453-2460. PubMed ID: 36042316
[TBL] [Abstract][Full Text] [Related]
59. A clinical update in polycythemia vera and essential thrombocythemia.
Tefferi A; Solberg LA; Silverstein MN
Am J Med; 2000 Aug; 109(2):141-9. PubMed ID: 10967156
[TBL] [Abstract][Full Text] [Related]
60. Treatment indications and choice of a platelet-lowering agent in essential thrombocythemia.
Barbui T; Finazzi G
Curr Hematol Rep; 2003 May; 2(3):248-56. PubMed ID: 12901347
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
